Alexandria Company for Pharmaceuticals and Chemical Industries SAE

Alexandria Company for Pharmaceuticals and Chemical Industries SAE maintains a strong liquidity position, with a current ratio of 1.92, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity FPT (free cash flow to total liabilities) is supported by a robust operating cash flow of EGP 165.3 million and free cash flow of EGP 35.0 million, which provides flexibility for operational and strategic initiatives.

In terms of profitability, the company's return on equity (ROE) of 10.3% and return on assets (ROA) of 6.14% are in line with the industry's preferred metrics, suggesting efficient use of equity and assets to generate returns. The operating margin of 21.8% (calculated from operating income of EGP 100.5 million on revenue of EGP 460.9 million) indicates a healthy margin structure, which is a key indicator of operational efficiency.

The company's revenue is primarily concentrated in its core pharmaceuticals segment, with no disclosed geographic diversification in the latest financial data. This concentration may expose the company to regional market risks, particularly in Egypt, where it is headquartered.

Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant revenue growth or decline expected in the next fiscal year. The company's capital expenditure of EGP -52.9 million suggests a focus on cost optimization rather than expansion in the near term.

The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and a debt-to-equity ratio of 0.0 further supports the company's strong financial position. The company has not issued any recent equity, and there are no indications of near-term dilution pressure.

Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly impact the company's operations or financial performance. The company continues to operate within its established business model, with no disclosed changes in its product portfolio or market strategy.

Revenue EGP 2.10B, +51,1% YoY; Operating income +40,2% YoY.

• ▍Revenue EGP 2.10B, +51,1% YoY
• ▍Operating income +40,2% YoY
• ▍Net income +36,4% YoY
• ▍Free cash flow +197,3% YoY
• ▍Net margin 10.7%

Revenue EGP 1.39B, +13,9% YoY; Operating income +23,2% YoY.

• ▍Revenue EGP 1.39B, +13,9% YoY
• ▍Operating income +23,2% YoY
• ▍Net income +27,9% YoY
• ▍Free cash flow −38,3% YoY
• ▍Net margin 11.9%

Revenue EGP 1.22B, −9,0% YoY; Operating income −33,2% YoY.

• ▍Revenue EGP 1.22B, −9,0% YoY
• ▍Operating income −33,2% YoY
• ▍Net income −34,4% YoY
• ▍Free cash flow +38 585,7% YoY
• ▍Net margin 10.6%

Revenue EGP 1.34B; Operating income EGP 257.4M.

• ▍Revenue EGP 1.34B
• ▍Operating income EGP 257.4M
• ▍Net margin 14.7%